Analysts Predict FHLC Will Hit $78
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Should l Buy PBH?
Source: NASDAQ.COM
ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PBH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PBH
Wall Street analysts forecast PBH stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 57.050
Low
66.00
Averages
76.00
High
86.00
Current: 57.050
Low
66.00
Averages
76.00
High
86.00
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Prestige Consumer to Acquire Breathe Right Brand for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare is set to acquire the Breathe Right brand and other OTC health products from Foundation Consumer Brands for $1.045 billion in cash, with the deal expected to close in the first half of fiscal 2027, indicating a proactive strategy in expanding its product portfolio.
- Financial Highlights: The acquired portfolio includes Dimetapp and Anbesol, generating $200 million in annual revenue and $95 million in EBITDA, suggesting that this acquisition will significantly enhance Prestige's financial foundation and competitive position in the market.
- Financing Strategy: Prestige plans to finance the acquisition using cash on hand and a new term loan, demonstrating flexibility in capital management and confidence in future growth, although it may impact short-term liquidity.
- Market Reaction: Following the acquisition announcement, Prestige Consumer Healthcare's stock rose 1.6% in premarket trading, reflecting investor optimism about the deal and its potential to drive further growth in the OTC market.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare has entered into a definitive agreement to acquire the Breathe Right brand and other brands from Foundation Consumer Healthcare for $1.045 billion, with an anticipated net cost of approximately $900 million after tax benefits, indicating the company's strategic expansion in the health consumer goods sector.
- Brand Value Analysis: Breathe Right is expected to represent about two-thirds of the revenue and profitability of the acquired portfolio, becoming the largest brand in Prestige's lineup, which will significantly enhance its market competitiveness and overall financial performance.
- Financing Strategy: The acquisition will be financed through cash on hand and a new Term Loan credit facility, demonstrating the company's financial prudence and confidence in future growth prospects.
- Market Reaction: In pre-market trading on the NYSE, Prestige shares rose by 1.57% to $61.00, reflecting positive investor sentiment and market confidence regarding the acquisition.
See More
Three Companies for Steady Wealth Growth
- Strong Performance of Spectrum Brands: In Q1 of fiscal 2026, Spectrum Brands reported an EPS of $1.40, exceeding expectations by 84%, with revenue reaching $677 million, indicating a recovery in its global pet care segment that is expected to drive future growth.
- Expansion Plans of Central Garden & Pet: Central Garden & Pet had a solid start to fiscal 2026, with management asserting that the current stock price is undervalued, announcing a $100 million expansion of its share buyback program, reflecting confidence in future growth.
- Acquisition Strategy of Prestige Consumer Healthcare: Prestige Consumer Healthcare achieved $283.4 million in revenue in Q3 of fiscal 2026, surpassing expectations despite economic challenges, and successfully acquired eye care supplier Pillar5 Pharma, further strengthening its market position.
- Long-term Wealth Building Potential: All three companies focus on brand acquisition and integration, demonstrating robust wealth growth potential through sustained profitability and cash flow generation in uncertain market conditions.
See More
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Health Care Stocks Decline Late Friday
- Overall Decline: Late Friday, the NYSE Health Care Index experienced a downturn, indicating increasing market concerns about the healthcare sector, which may negatively impact investor confidence.
- Market Reaction: The decline in healthcare stocks may be linked to overall economic uncertainty, as investors anticipate potential policy changes that could lead to capital outflows from the sector, thereby affecting stock performance.
- Industry Impact: The weak performance of the healthcare sector could hinder related companies' financing capabilities and market valuations, especially under the current economic conditions where operational pressures are heightened.
- Investor Strategy Adjustment: As healthcare stocks decline, investors may reassess their portfolios, considering reallocating funds to other sectors with greater growth potential to mitigate risks associated with market volatility.
See More
Prestige Consumer to Acquire Breathe Right Brand for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare is set to acquire the Breathe Right brand and other OTC health products from Foundation Consumer Brands for $1.045 billion in cash, with the deal expected to close in the first half of fiscal 2027, indicating a proactive strategy in expanding its product portfolio.
- Financial Highlights: The acquired portfolio includes Dimetapp and Anbesol, generating $200 million in annual revenue and $95 million in EBITDA, suggesting that this acquisition will significantly enhance Prestige's financial foundation and competitive position in the market.
- Financing Strategy: Prestige plans to finance the acquisition using cash on hand and a new term loan, demonstrating flexibility in capital management and confidence in future growth, although it may impact short-term liquidity.
- Market Reaction: Following the acquisition announcement, Prestige Consumer Healthcare's stock rose 1.6% in premarket trading, reflecting investor optimism about the deal and its potential to drive further growth in the OTC market.
See More
Prestige Consumer Healthcare Acquires Breathe Right for $1.045 Billion
- Acquisition Overview: Prestige Consumer Healthcare has entered into a definitive agreement to acquire the Breathe Right brand and other brands from Foundation Consumer Healthcare for $1.045 billion, with an anticipated net cost of approximately $900 million after tax benefits, indicating the company's strategic expansion in the health consumer goods sector.
- Brand Value Analysis: Breathe Right is expected to represent about two-thirds of the revenue and profitability of the acquired portfolio, becoming the largest brand in Prestige's lineup, which will significantly enhance its market competitiveness and overall financial performance.
- Financing Strategy: The acquisition will be financed through cash on hand and a new Term Loan credit facility, demonstrating the company's financial prudence and confidence in future growth prospects.
- Market Reaction: In pre-market trading on the NYSE, Prestige shares rose by 1.57% to $61.00, reflecting positive investor sentiment and market confidence regarding the acquisition.
See More
Three Companies for Steady Wealth Growth
- Strong Performance of Spectrum Brands: In Q1 of fiscal 2026, Spectrum Brands reported an EPS of $1.40, exceeding expectations by 84%, with revenue reaching $677 million, indicating a recovery in its global pet care segment that is expected to drive future growth.
- Expansion Plans of Central Garden & Pet: Central Garden & Pet had a solid start to fiscal 2026, with management asserting that the current stock price is undervalued, announcing a $100 million expansion of its share buyback program, reflecting confidence in future growth.
- Acquisition Strategy of Prestige Consumer Healthcare: Prestige Consumer Healthcare achieved $283.4 million in revenue in Q3 of fiscal 2026, surpassing expectations despite economic challenges, and successfully acquired eye care supplier Pillar5 Pharma, further strengthening its market position.
- Long-term Wealth Building Potential: All three companies focus on brand acquisition and integration, demonstrating robust wealth growth potential through sustained profitability and cash flow generation in uncertain market conditions.
See More
